Abstract #1831

Pyruvate Infusion Rates for Hyperpolarized Metabolite Imaging of Human Heart

Jeffry R. Alger^1,2,3,4, Jae Mo Park¹, Junjie Ma¹, Mahitha Roy¹, Crystal Harrison¹, James Ratnakar¹, Albert Chen⁵, Galen Reed⁶, A. Dean Sherry^1,7, Vlad Zaha¹, and Craig R. Malloy^1,8

¹Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, United States, ²Neurology, University of California, Los Angeles, Los Angeles, CA, United States, ³NeuroSpectroScopics LLC, Sherman Oaks, CA, United States, ⁴Hura Imaging Inc, Los Angeles, CA, United States, ⁵GE Healthcare, Toronto, ON, Canada, ⁶GE Healthcare, Dallas, TX, United States, ⁷Chemistry, University of Texas at Dallas, Richardson, TX, United States, ⁸Cardiology, Veterans Affairs North Texas Healthcare System, Dallas, TX, United States

MRI/MRS metabolic tracing in human heart with hyperpolarized ¹³C-enriched pyruvate is feasible, but there remains a need to define the optimal infusion timing that accommodates both short polarization lifetime and subject comfort. Typical studies have used a 5.0 cm³/sec pyruvate infusion rate. We hypothesized that slower infusion is feasible because of the in vitro versus intravascular T1 difference and because vascular properties limit the rate of pyruvate delivery from the infusion site to the heart. Vascular dynamic simulations and preliminary human investigations suggest that a 2.0 cm³/sec pyruvate infusion rate be effectively used.

This abstract and the presentation materials are available to members only; a login is required.

Join Here